person · Reporting owner

Noble James

Disclosed activity across 3 companies

Tapewire entity: 73055
SEC CIK: 0001388000

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Adaptimmune Therapeutics PLCADAP · Entity 9824	Director	July 01, 2022	July 01, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adaptimmune Therapeutics PLC

Report date July 01, 2022 · Filed July 01, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2032-07-01	Direct	710,711	Reported balance After 2022-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-07-01 · Grant · Acquired 710,711 · Balance 710,711 F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

GW PHARMACEUTICALS PLC

Report date May 05, 2021 · Filed May 07, 2021

Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-05-05 transaction · row 1 1 source row Row 1 · 2021-05-05 · Disposition to issuer · Disposed 27,492 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.81 · Expires 2027-01-06	Direct	Reported balance After 2021-05-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-05-05 · Disposition to issuer · Disposed 18,636 · Balance 0 F3: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-01-06	Direct	Reported balance After 2021-05-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-05-05 · Disposition to issuer · Disposed 9,168 · Balance 0 F3: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2028-01-03	Direct	Reported balance After 2021-05-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-05-05 · Disposition to issuer · Disposed 17,676 · Balance 0 F3: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2028-01-03	Direct	Reported balance After 2021-05-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-05-05 · Disposition to issuer · Disposed 10,740 · Balance 0 F3: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01	Direct	Reported balance After 2021-05-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-05-05 · Disposition to issuer · Disposed 16,548 · Balance 0 F3: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-03-01	Direct	Reported balance After 2021-05-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-05-05 · Disposition to issuer · Disposed 9,432 · Balance 0 F3: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2030-06-04	Direct	Reported balance After 2021-05-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-05-05 · Disposition to issuer · Disposed 34,416 · Balance 0 F3: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2031-02-22	Direct	Reported balance After 2021-05-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-05-05 · Disposition to issuer · Disposed 22,464 · Balance 0 F3: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.

Filing footnotes · ownership attribution and instrument terms

F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).

F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.

F3: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.

LAVA Therapeutics NV

Report date November 13, 2025 · Filed November 17, 2025

Section 16 reporting ended · disclosed 2025-11-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2035-02-12	Direct	0	Reported balance After 2025-11-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-11-13 · Disposition to issuer · Disposed 33,390 · Balance 0 F1: This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.

Filing footnotes · ownership attribution and instrument terms

F1: This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 13, 2025 Filed Nov 17, 2025 16:30 UTC	LAVA Therapeutics NV LVTX · Entity 73047	Disposition to issuerShare Options (Right to Buy) · Derivative	33,390	$0.00 Strike: $0.93	$0.00	Disclosure SEC source: 0001388000-25-000005 · form4-11172025_041113.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 33,390 shares Expires 2035-02-12 F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option. Read SEC document
February 13, 2025 Filed Feb 18, 2025 20:15 UTC	LAVA Therapeutics NV LVTX · Entity 73047	GrantCommon Shares (Right to Buy) · Derivative	33,390	$0.00 Strike: $0.93	$0.00	Disclosure SEC source: 0001415889-25-004530 · form4-02182025_080216.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,390 Underlying: Common Shares · 33,390 shares Expires 2035-02-12 F1 · derivative.exercise_date: 100% of the shares underlying the option will vest on February 13, 2026, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date. Read SEC document
July 01, 2022 Filed Jul 1, 2022 17:02 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	710,711	$0.00 Strike: $0.28	$0.00	Disclosure SEC source: 0001104659-22-076897 · tm2220260-4_4seq1.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,711 Underlying: Ordinary Shares · 710,711 shares Expires 2032-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
July 01, 2021 Filed Jul 2, 2021 17:02 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	379,788	$0.00 Strike: $0.71	$0.00	Disclosure SEC source: 0001104659-21-088969 · tm2121284-4_4seq1.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,788 Underlying: Ordinary Shares · 379,788 shares Expires 2031-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	22,464	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018665 · doc4.xml · derivative · entry 9 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,464 shares Expires 2031-02-22 F3 · price: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	34,416	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018665 · doc4.xml · derivative · entry 8 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 34,416 shares Expires 2030-06-04 F3 · price: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	9,432	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018665 · doc4.xml · derivative · entry 7 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,432 shares Expires 2029-03-01 F3 · price: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	16,548	Not disclosed Strike: $14.33	Not disclosed	Disclosure SEC source: 0000899243-21-018665 · doc4.xml · derivative · entry 6 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 16,548 shares Expires 2029-03-01 F3 · price: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	10,740	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018665 · doc4.xml · derivative · entry 5 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,740 shares Expires 2028-01-03 F3 · price: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	17,676	Not disclosed Strike: $11.17	Not disclosed	Disclosure SEC source: 0000899243-21-018665 · doc4.xml · derivative · entry 4 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,676 shares Expires 2028-01-03 F3 · price: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	9,168	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018665 · doc4.xml · derivative · entry 3 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,168 shares Expires 2027-01-06 F3 · price: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	18,636	Not disclosed Strike: $9.81	Not disclosed	Disclosure SEC source: 0000899243-21-018665 · doc4.xml · derivative · entry 2 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 18,636 shares Expires 2027-01-06 F3 · price: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerOrdinary Shares	27,492	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-018665 · doc4.xml · nonDerivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2 · price: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Read SEC document
February 22, 2021 Filed Feb 24, 2021 18:44 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	22,464	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-008083 · doc4.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,464 Underlying: Ordinary Shares · 22,464 shares Expires 2031-02-22 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F3 · derivative.exercise_date: These share options will vest in three equal annual installments beginning on February 22, 2022. F4 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F4 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document
July 01, 2020 Filed Jul 1, 2020 17:08 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	179,785	$0.00 Strike: $1.67	$0.00	Disclosure SEC source: 0001104659-20-079787 · a4.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,785 Underlying: Ordinary Shares · 179,785 shares Expires 2030-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:05 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	34,416	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-015699 · doc4.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,416 Underlying: Ordinary Shares · 34,416 shares Expires 2030-06-04 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F3 · derivative.exercise_date: These share options will vest in three equal annual installments beginning on June 4, 2021. Read SEC document
May 29, 2020 Filed Jun 2, 2020 21:30 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	SaleAmerican Depositary Shares	500,000	$9.33	$4,666,000.00	Disclosure SEC source: 0001104659-20-069142 · a4.xml · nonDerivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019. F3 · shares: The ADSs reported in this Column 4 represent solely those ADSs that were sold pursuant to a Rule 10b5-1 trading plan. Additionally, the reporting person holds 8,145,700 ordinary shares and share options covering an aggregate of 9,137,960 ordinary shares of the Issuer. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $9.02 to $10.13, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote. Read SEC document
April 01, 2020 Filed Apr 1, 2020 19:06 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	31,000	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001104659-20-042013 · a4.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Ordinary Shares · 31,000 shares Expires 2030-04-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.36 based on an exchange rate of $U.S. 1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document
January 13, 2020 Filed Jan 15, 2020 20:01 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	SaleAmerican Depositary Shares	200,000	$5.00	$1,000,000.00	Disclosure SEC source: 0001104659-20-004419 · a4.xml · nonDerivative · entry 2 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019. F3 · price: These ADSs were sold in multiple transactions at a price of $5.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote. Read SEC document
January 13, 2020 Filed Jan 15, 2020 20:01 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	SaleAmerican Depositary Shares	100,000	$4.00	$400,000.00	Disclosure SEC source: 0001104659-20-004419 · a4.xml · nonDerivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019. F2 · price: These ADSs were sold in multiple transactions at a price of $4.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote. Read SEC document
May 24, 2019 Filed May 29, 2019 20:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	34,056	$0.00 Strike: $4.86	$0.00	Disclosure SEC source: 0000899243-19-015096 · doc4.xml · derivative · entry 10 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5 Underlying: Ordinary Shares · 34,056 shares Expires 2025-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 24, 2019. Read SEC document
May 24, 2019 Filed May 29, 2019 20:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	34,061	$0.00 Strike: $4.86	$0.00	Disclosure SEC source: 0000899243-19-015096 · doc4.xml · derivative · entry 9 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 34,061 shares Expires 2025-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 24, 2019. Read SEC document
May 24, 2019 Filed May 29, 2019 20:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	14,479	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-015096 · doc4.xml · derivative · entry 8 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,479 shares Expires 2025-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 24, 2019. Read SEC document
May 24, 2019 Filed May 29, 2019 20:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	13,800	$15.58	$215,004.00	Disclosure SEC source: 0000899243-19-015096 · doc4.xml · nonDerivative · entry 7 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2019. F8 · price: The price reported in Column 4 is a weighted average price per ordinary share ($186.99 per ADS). These shares were sold in multiple transactions at prices ranging from $186.58 per ADS (or $15.55 per ordinary share) to $187.43 per ADS (or $15.62 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 24, 2019 Filed May 29, 2019 20:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	3,600	$15.49	$55,764.00	Disclosure SEC source: 0000899243-19-015096 · doc4.xml · nonDerivative · entry 6 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,300 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2019. F7 · price: The price reported in Column 4 is a weighted average price per ordinary share ($185.88 per ADS). These shares were sold in multiple transactions at prices ranging from $185.40 per ADS (or $15.45 per ordinary share) to $186.20 per ADS (or $15.52 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 24, 2019 Filed May 29, 2019 20:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	10,200	$15.32	$156,264.00	Disclosure SEC source: 0000899243-19-015096 · doc4.xml · nonDerivative · entry 5 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,900 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2019. F6 · price: The price reported in Column 4 is a weighted average price per ordinary share ($183.78 per ADS). These shares were sold in multiple transactions at prices ranging from $183.58 per ADS (or $15.30 per ordinary share) to $184.15 per ADS (or $15.35 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 24, 2019 Filed May 29, 2019 20:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	41,796	$15.26	$637,806.96	Disclosure SEC source: 0000899243-19-015096 · doc4.xml · nonDerivative · entry 4 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,100 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2019. F5 · price: The price reported in Column 4 is a weighted average price per ordinary share ($183.18 per ADS). These shares were sold in multiple transactions at prices ranging from $182.58 per ADS (or $15.22 per ordinary share) to $183.54 per ADS (or $15.30 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 24, 2019 Filed May 29, 2019 20:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	13,200	$15.17	$200,244.00	Disclosure SEC source: 0000899243-19-015096 · doc4.xml · nonDerivative · entry 3 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,896 F3 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2019. F4 · price: The price reported in Column 4 is a weighted average price per ordinary share ($182.00 per ADS). These shares were sold in multiple transactions at prices ranging from $181.56 per ADS (or $15.13 per ordinary share) to $182.54 per ADS (or $15.21 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 24, 2019 Filed May 29, 2019 20:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	68,117	$4.86	$331,327.90	Disclosure SEC source: 0000899243-19-015096 · doc4.xml · nonDerivative · entry 2 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 24, 2019. Read SEC document
May 24, 2019 Filed May 29, 2019 20:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	14,479	$0.00	$18.82	Disclosure SEC source: 0000899243-19-015096 · doc4.xml · nonDerivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 24, 2019. Read SEC document
May 16, 2019 Filed May 17, 2019 18:00 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	Exercise / conversionOrdinary Shares with a nominal value of GBP0.001 per share	1,773,100	$0.14	$253,553.30	Disclosure SEC source: 0001104659-19-030337 · a4.xml · nonDerivative · entry 1 Noble James · CIK 0001388000 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,773,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person. F2 · price: The price reported in Column 4 of $0.143 per ordinary share is derived from the option purchase price paid on May 16, 2019 of GBP 0.112 per ordinary share. F1 · balance_after: The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:05 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantStock Options · Derivative	3,144	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-006333 · doc4.xml · derivative · entry 4 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:05 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantStock Options · Derivative	3,144	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-006333 · doc4.xml · derivative · entry 3 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:05 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantStock Options · Derivative	3,144	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-006333 · doc4.xml · derivative · entry 2 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:05 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantStock Options · Derivative	16,548	$0.00 Strike: $14.33	$0.00	Disclosure SEC source: 0000899243-19-006333 · doc4.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,548 Underlying: Ordinary Shares · 16,548 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · security: The reported options are options to purchase American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · derivative.exercise_price: The exercise price reported is price per ordinary share converted from price per ADS ($172.01). Read SEC document
January 04, 2019 Filed Jan 8, 2019 21:00 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	561,792	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-19-001300 · a4.xml · derivative · entry 2 Noble James · CIK 0001388000 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,792 Underlying: Ordinary Shares · 561,792 shares Expires 2029-01-04 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 140,448 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 140,448 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023. Read SEC document
January 04, 2019 Filed Jan 8, 2019 21:00 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	2,515,536	$0.00 Strike: $0.89	$0.00	Disclosure SEC source: 0001104659-19-001300 · a4.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,515,536 Underlying: Ordinary Shares · 2,515,536 shares Expires 2029-01-04 F1 · derivative.exercise_price: The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 628,884 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 52,404 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 52,512 Ordinary Shares on January 4, 2023. Read SEC document
January 12, 2018 Filed Jan 17, 2018 17:20 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	384,120	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-18-002673 · a4.xml · derivative · entry 2 Noble James · CIK 0001388000 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,120 Underlying: Ordinary Shares · 384,120 shares Expires 2028-01-12 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 96,030 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 96,030 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022. Read SEC document
January 12, 2018 Filed Jan 17, 2018 17:20 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	1,719,936	$0.00 Strike: $1.30	$0.00	Disclosure SEC source: 0001104659-18-002673 · a4.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,719,936 Underlying: Ordinary Shares · 1,719,936 shares Expires 2028-01-12 F1 · derivative.exercise_price: The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 429,984 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 35,832 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022. Read SEC document
January 13, 2017 Filed Jan 18, 2017 17:00 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	2,072,976	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001104659-17-002818 · a4.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,072,976 Underlying: Ordinary Shares · 2,072,976 shares Expires 2027-01-13 F1 · derivative.exercise_price: The exercise price was converted from GBP0.59 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 518,244 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 43,187 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.